Lymphoma

Expanded use of chimeric antigen receptor T cells for cancer treatment requires that less expensive therapies be developed faster using multiple manufacturing models, according to an FDA official.

The FDA granted priority review to tisagenlecleucel, a chimeric antigen receptor T-cell therapy, for treatment of adults with relapsed or refractory follicular lymphoma who received two prior lines of therapy.

The FDA cleared an investigational new drug application for PRGN-3007, a chimeric antigen receptor T-cell therapy for patients with advanced hematologic malignancies or solid tumors that express receptor tyrosine kinase-like orphan receptor 1.

The sense of urgency surrounding the COVID-19 pandemic led to speedy development of several vaccines against the SARS-CoV-2 virus.

A collaborative team of cancer experts from leading academic institutions and organizations has released recommendations for optimal protection against COVID-19 among individuals with blood cancer.

American Association for Cancer Research urged the CDC to expand availability of COVID-19 booster vaccinations to caregivers and other individuals who share a home with patients with cancer.

More than half of patients who received a single dose of CTX110 for relapsed or refractory large B-cell lymphoma responded to therapy, according to topline data released by the agent’s manufacturer.

Patients with lymphoid malignancies who received anti-CD20 therapy within the previous year did not demonstrate antibody responses to the messenger RNA COVID-19 vaccines, according to study results published in Blood Advances.

The FDA placed a clinical hold on a series of clinical trials that use Allogene Therapeutics’ AlloCAR T chimeric antigen receptor T-cell therapies, according to a press release from the manufacturer.

ASH will honor Donna S. Neuberg, ScD, with the 2021 Exemplary Service Award at this year’s ASH Annual Meeting, scheduled for Dec. 11-14.